Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics
- 1 May 1997
- journal article
- Published by Elsevier in Fibrinolysis and Proteolysis
- Vol. 11 (3) , 129-135
- https://doi.org/10.1016/s0268-9499(97)80057-4
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial InfarctionCirculation, 1996
- Superficial Accumulation of Plasminogen During Plasma Clot LysisCirculation, 1995
- More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial InfarctionCirculation, 1995
- Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.Journal of Clinical Investigation, 1995
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- BM 06.022: A Novel Recombinant Plasminogen ActivatorCardiovascular Drug Reviews, 1993
- Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosisBlood Coagulation & Fibrinolysis, 1992
- “Plasminogen steal” and clot lysisJournal of the American College of Cardiology, 1992
- Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosisJournal of the American College of Cardiology, 1992
- Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine ModelJournal of Cardiovascular Pharmacology, 1991